SOFTWARE VENDOR APPROVAL FOR CALIFORNIA STATE REPORTING

VENDORS APPROVED FOR 2022
CNExT Version 2.22.1 (full approval, October 6, 2022)
METRIQ Version 3.41 (full approval, November 14, 2022)
ERS Version 22.0 (full approval, November 14, 2022)

VENDORS APPROVED FOR 2021
KACI® 2.0 from NeuralFrame (full approval, March 21, 2022)
Onco Version 4.6.0 (full approval, March 21, 2022)
ERS Version 21.0 (full approval, January 6, 2022)
Elekta Impac’s METRIQ Version 3.31 (full approval, January 6, 2022)
CNExT Version 2.0 (full approval, November 1, 2021)

VENDORS APPROVED FOR 2018
ERS Version 18.0 (full approval, October 30, 2019)
CNExT Version 1.18.0 (full approval, March 25, 2019)
Elekta Impac’s METRIQ Version 3.20 (full approval November 6, 2019)
Elekta Impac’s METRIQ Version 3.10 (full approval April 15, 2019)

VENDORS APPROVED FOR 2016
OncoVersion V4.3.3 (full approval, December 22, 2016)
CRStar by ERS Version 16.0 (full approval December 9, 2016)
Elekta Impac’s METRIQ Version 2.86 (full approval December 9, 2016)
CNExT Version 15.0 (full approval August 2, 2016)

VENDORS APPROVED FOR 2015
CRStar by ERS Version 15.0 (partial approval – approved for new, follow-up and deletion records only. Not approved for Correction Records July 14, 2016)
Elekta Impac’s METRIQ Version 2.84 (full approval June 20, 2016)
Onco Version V4.3.2 (full approval August 28, 2015)
Elekta Impac’s METRIQ Version 2.82 (full approval April 9, 2015)
CNExT Version 1.16.0 (full approval March 30, 2015)

VENDORS APPROVED FOR 2014
ERS Version 10.9 (full approval 8/4/14)
Elekta Impac’s METRIQ Version 2.80 (full approval July 11, 2014)
CNExT Version 1.15.0 (full approval April 4, 2014)

VENDORS APPROVED FOR 2013
ERS Version 10.8 (full approval February 28, 2014)
ERS Version 10.7 (full approval August 29, 2013)
Onco Version 4.2 (full approval August 29, 2013)
Elekta Impac’s METRIQ Version 2.60 (full approval June 19, 2013)

VENDORS APPROVED FOR 2012
CNExT Version 1.12 (full approval – May 24, 2012)
Elekta Impac’s METRIQ Version 2.50 (full approval – November 30, 2012) ERS 10.5 Single Hospital and Multi-Hospital (partial approval - approved for new, follow-up and deletion records only, not approved for Correction records - June 29, 2012; correction records approved – September 25, 2012)

VENDORS APPROVED FOR 2011
CNExT Version 1.11 (full approval – June 17, 2011)
Elekta Impac’s METRIQ Version 2.20 (full approval – September 21, 2011)
ERS 10.3 and ERSMH 10.3 (full approval – December 20, 2011)

VENDORS APPROVED FOR 2010
CNExT Version 1.10.1.11 (full approval – October 28, 2010)
Elekta Impac’s METRIQ Version 2.00 (full approval – December 2, 2010)
Elekta Impac’s METRIQ Version 2.10 (full approval – December 14, 2010)
ERS 10.0 and ERSMH 10.0 (full approval – March 11, 2011)

VENDORS APPROVED FOR 2009
CNExT (full approval – April 2009)
IMPAC (full approval – May 11, 2009)
ERS (new case record approved – October 28, 2009; correction and follow up records approved – December 1, 2009)

VENDORS APPROVED FOR 2008
CNExT (full approval – April 29, 2008) IMPAC (full approval – May 4, 2008)
ERS (full approval – September 10, 2008)

VENDORS APPROVED FOR 2007
CNExT (full approval – February 2007)
IMPAC (provisional approval – June 2007)

VENDORS APPROVED FOR 2006
CNExT (full approval – January 30, 2006) IMPAC (full approval – April 28, 2006)

VENDORS APPROVED FOR 2005
CNExT (full approval)
IMPAC (full approval)
ERS (new case record only)
California Cancer Registry Revised 9-25-2012

VENDORS APPROVED FOR 2004
CNExT (full approval)
Electronic Registry Systems (new case record approved; follow-up record approved with contingency)

**VENDORS APPROVED FOR 2003**
CNExT (full approval)
Electronic Registry Systems (approved)
IMPAC (approved with contingency)

**VENDORS APPROVED FOR 2002**
CNExT (full approval)
Electronic Registry Systems (full approval)

*For information on how to obtain approval for reporting cancer data to the California Cancer Registry please refer to* Cancer Reporting in California Standards for Automated Reporting California Cancer Reporting System Standards: Volume II.